A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

6.6K views

⸱

DOI:

10.3791/60848

⸱

January 30th, 2020

In This Article

Summary

Described here is a method for targeted, markerless gene deletion in Chlamydia trachomatis using floxed cassette allelic exchange mutagenesis, FLAEM.

Abstract

Chlamydia trachomatis is an obligate intracellular pathogen that has been historically difficult to genetically manipulate. Definitive progress in elucidating the mechanisms that C. trachomatis use to create and maintain a privileged intracellular niche has been limited due to a lack of genetic tools. Fortunately, there have recently been several new advances in genetic manipulation techniques. Among these is the development of fluorescence-reported allelic exchange mutagenesis (FRAEM). This method allows targeted gene deletion coupled with insertion of a selection cassette encoding antibiotic resistance and green fluorescent protein (GFP). Reliance on this strategy can be complicated when targeting genes within polycistronic operons due to the potential of polar effects on downstream genes. Floxed cassette allelic exchange mutagenesis (FLAEM), the protocol for which is described here, was developed to alleviate cassette-induced polar effects. FLAEM utilizes Cre-loxP genome editing to remove the selection cassette after targeted deletion by allelic exchange. The resulting strains contain markerless gene deletions of one or more coding sequences. This technique facilitates direct assessment of gene function and expands the repertoire of tools for genetic manipulation in C. trachomatis.

Introduction

Chlamydia trachomatis is the leading cause of bacterial sexually transmitted disease and represents a significant burden to human health. Over 100 million people are infected every year with C. trachomatis1. Approximately 70% of the infections in women are asymptomatic despite detrimental reproductive health effects, such as pelvic inflammatory disease, ectopic pregnancy, and/or infertility. Disease sequela are directly related to immunopathology initiated by C. trachomatis infection2. An efficacious vaccine has yet to be developed; therefore, understanding the function of bacterial virulence f....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Design and Assembly of pSUmC-4.0 with Homology Arms Specific to the Gene of Interest

  1. Identify ~3 kb regions directly upstream and downstream of the gene targeted for deletion to serve as the 5' and 3' homology arms for homologous recombination (Figure 1).
  2. Design PCR primers to 1) amplify the 3 kb 5' homology arm from chlamydial genomic DNA and 2) contain a 15–30 bp overhang specific to pSUmC-4.0 when digested at the Sall restriction enzyme site. Ensure that the primer regions overlapping with pSUmC-4.0 have melting temperatures of 55 °C and that hairpin melting temperatures for the entire pr....

Access restricted. Please log in or start a trial to view this content.

Results

The method for markerless gene deletion in C. trachomatis using FLAEM is reliant upon careful cloning and transformation techniques. Successful allelic recombination is an essential first step and requires the identification and insertion of homology arms into the pSUmC-4.0 cloning vector (Figure 1). An essential second step for markerless gene deletion is removal of the fluorescence reporter and antibiotic selection cassette by Cre-lox genome editing, represented in

Access restricted. Please log in or start a trial to view this content.

Discussion

The protocol described here for the generation of markerless gene deletions in C. trachomatis by FLAEM allows targeted deletion of nonessential genes and eliminates cassette-induced polar effects. The protocol relies upon careful design of 5' and 3' homology arms inserted into the pSUmC 4.0 suicide vector, efficient transformation of C. trachomatis, and careful screening of isolated mutant strains. Successful genome engineering via this method results in bacteria that are nonfluorescent and cont.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

This work was supported by Public Health Service grants from the National Institute of Health, NIAID (grants A1065530 and Al124649), to K.A. Fields.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
AgaroseKSE ScientificBMK-A1705Molecular Biology Grade
Anhydrotetracycline hydrochlorideACROS Organics233131000
CaCl2 Buffer10 mM Tris pH 7.4, 50 mM Calcium Chloride Dihydrate
Calcium Chloride DihydrateSigmaC7902-500GSuitable for cell culture
CycloheximideSigma7698-1G
dam-/dcm- Competent E. coliNew England BioLabsC2925H
DMSOATCC4-XSterile filtered cell culture tested
Glutamic acidSigmaG8415-100GL-Glutamic acid
Growth Media #1RPMI 1640 media supplemented with 10 % (vol/vol) heat-inactivated fetal bovine serum (FBS).
Growth Media #2RPMI 1640 media supplemented with 10 % (vol/vol) heat-inactivated fetal bovine serum (FBS) and 1 µg/mL cycloheximide
Hanks' Balanced Salt Solution (HBSS) (1x)Gibco24020-117
Heat Inactivated Fetal Bovine Serum Qualified One Shot (FBS)GibcoA38402-02
McCoy CellsATCCCRL-1696
Monarch Plasmid Miniprep KitNew England BioLabsT1010SSmall scale DNA purification
NaH2PO4SigmaS3139-250GSodium phosphate monobasic
Na2HPO4SigmaS5136-500GSodium phosphate dibasic
NEB 10-beta Electrocompetent E. coli CellsNew England BioLabsC3020K
NEBuilder HiFi DNA assembly Cloning KitNew England BioLabsE5520SGibson Assembly Kit
Penicillin G sodium saltSigmaP3032-10MUBioreagent suitable for cell culture
QIAGEN Plasmid Maxi KitQIAGEN12162Large scale DNA purification
Q5 Hot Start High-Fidelity DNA PolymeraseNew England BioLabsM0515Fragment PCR Polymerase
RPMI 1640 Medium (1x)Gibco11875-093Containing 2mM L-glutamine
Sall-HFNew England BioLabsR3138S
Sbfl-HFNew England BioLabsR3642S
Selection Media #1RMPI 10 % FBS, 1 µg/mL cycloheximide, 500 µg/mL spectinomycin, and 50 ng/mL anhydrous tetracycline dissolved in DMSO
Selection Media #2RMPI 10 % FBS, 1 µg/mL cycloheximide, 500 µg/mL spectinomycin
Selection Media #3RPMI 10 % FBS, 1 µg/mL cycloheximide, 50 ng/mL aTc, and 0.6 µg/mL penicillin
Sodium Acetate Buffer SolutionSigmaS7899-100ML3M
SOC Outgrowth MediumNew England BioLabsB9020SVIAL
Spectinomycin dihydrochloride pentahydrate, Cell Culture GradeAlfa AesarJ61820
SucroseSigmaS1888-1KGBioreagent suitable for cell culture
Sucrose-Phosphate-Glutamate Buffer (SPG)37.5g sucrose, 1.25 g Na2HPO4, 0.18 g NaH2PO4, 0.36 glutamic acid for 500 ml tissue culture grade water
TrisAMRESCO0497-5KGUltrapure grade
Trypsin-EDTA (1x)Gibco25200-0560.25%
WaterSigmaW3500-500MLSterile-filtered, BioReagent, Suitable for cell culture

References

  1. World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections: 2008: World Health Organization. Sexual and Reproductive Health Matters. 20, World Health Organization. World Health Organization, Department of Reproductive Health and Research, 2012 ISBN 978 92 4 1503839 207-208 (2012).
  2. Stephen, R. S.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Cre-loxP Genome EditingHomologous RecombinationDNA AssemblyEpifluorescence MicroscopyQuantitative PCRWestern BlottingWhole Genome Sequencing